Cell therapy (TCR-T) · Kills target cells, directed at PRAME · developed by Immatics US
Anzutresgene autoleucel is an autologous T-lymphocyte therapy genetically modified with a lentiviral vector encoding a T-cell receptor specific for PRAME, a tumor-associated antigen overexpressed in a variety of cancers. After infusion, the modified cells recognize PRAME-expressing cancer cells and mediate a cytotoxic T-lymphocyte response against them. It is studied in melanoma and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06743126 | Phase 3 | Melanoma, Cutaneous Malignant | Recruiting | IMTX |
| NCT03686124 | Phase 1/2 | Refractory Cancer | Recruiting | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerMelanoma, Cutaneous MalignantRecurrent CancerRefractory CancerSolid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →